News

In a presentation during the 16th Annual Winter Lung Conference™, Gregory J. Riely, MD, PhD, discussed the spectrum of activity of many of these FDA-approved EGFR TKIs.

A recent meta-analysis has found no noticeable difference in immunotherapy's efficacy based on patient sex.

CancerCare celebrated its 75th anniversary by revealing a new campaign "If It Matters To You, It Matters To Us."

Take a look back at the top 5 Oncology Nursing News stories for January 2019.

The FDA has expanded the indication for pemetrexed (Alimta) injection in combination with pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.

Immunotherapy agents may soon combine with VEGF TKIs to redefine the frontline standard for treatment of metastatic renal cell carcinoma (mRCC).

$200,000 V Scholar Grant Awarded for Research Related to Blood Cancers

The phase III AIM2CERV trial investigating axalimogene filolisbac (AXAL) in patients with cervical cancer has been placed on partial clinical hold by the FDA.

The FDA recommends that no new patients with advanced soft tissue sarcoma be treated with the combination of olaratumab (Lartruvo) plus doxorubicin.

Neoadjuvant chemotherapy with dose-dense MVAC extends overall survival compared with other chemo regimens in bladder cancer treated with cystectomy.

In 2018, the V Foundation awarded $25 million for cutting-edge cancer research.

The FDA has approved the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Pembrolizumab (Keytruda) was found to reduce the risk of death by 31% in patients with PD-L1–positive (combined positive score [CPS] ≥10) advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, according to phase III findings of the KEYNOTE-181 trial.

Patients with previously untreated hepatocellular carcinoma (HCC) lived twice as long if they responded to TKI therapy vs. patients who did not achieve an objective response.

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly with the use of TAS-102 combination therapy.

The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer (BTC) who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

New initiatives boost awareness and fundraising: Kicks to Beat Cancer, Craig Sager Style Day, Blizzard/Overwatch League Season Preview and WeRateDogs “H*ck Cancer” campaign.

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab (Keytruda), trastuzumab (Herceptin), and chemotherapy, a small clinical trial showed.

The FDA has granted umbralisib (TGR-1202) a breakthrough therapy designation for the treatment of adult patients with marginal zone lymphoma (MZL) who have received 1 prior anti-CD20 regimen, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.

Preliminary findings from the SLI phase of the BEACON CRC trial show tri-drug combo has durable response in patients with BRAF V600E-mutant metastatic CRC.

The FDA has granted an approval to SB3 (Ontruzant; trastuzumab-dttb), a trastuzumab (Herceptin) biosimilar, for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

The FDA has issued a letter about a possible risk of increased mortality among patients with a type of arterial disease who have paclitaxel-coated implants.

Nivolumab (Opdivo) significantly improved overall survival (OS) versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine plus platinum-based therapy, according to topline findings of the phase III ATTRACTION-3 study.

The FDA has accepted a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq), carboplatin, and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

Payer reimbursement requirements, uncertainties in reform policy, and cost of new treatments viewed as top threats.

Half of patients diagnosed with advanced non-small cell lung cancer were alive 6.8 years after diagnosis, according to new study findings.

The cancer death rate declined 27% in the United States from 1991 to 2016, as reported by the American Cancer Society in its annual report, in part due to the significant decline in smoking and an increase in advances for early cancer detection and screening.

The FDA has granted a breakthrough therapy designation to zanubrutinib (BGB-3111) for use in some patients with mantle cell lymphoma.

The FDA has approved cabozantinib (Cabometyx) to treat hepatocellular carcinoma in patients who previously received sorafenib (Nexavar).

UGN-101 demonstrated a 57% complete response rate in some patients with urothelial cancer, according to findings from the phase III OLYMPUS trial.